Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CFO Eric Bjerkholt sold 5,000 shares of the company's stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the sale, the chief financial officer owned 42,181 shares in the company, valued at approximately $5,156,627.25. This represents a 10.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eric Bjerkholt also recently made the following trade(s):
- On Monday, June 8th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.82, for a total transaction of $469,100.00.
Mirum Pharmaceuticals Trading Up 0.2%
Mirum Pharmaceuticals stock opened at $128.57 on Thursday. The stock has a 50-day moving average price of $105.26 and a 200 day moving average price of $97.20. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The stock has a market cap of $7.84 billion, a PE ratio of -9.45 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 52 week low of $50.25 and a 52 week high of $129.00.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The company had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. During the same period last year, the company posted ($0.30) EPS. The business's revenue for the quarter was up 43.3% on a year-over-year basis. Equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on MIRM shares. Raymond James Financial reaffirmed a "strong-buy" rating and set a $165.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Royal Bank Of Canada boosted their price objective on shares of Mirum Pharmaceuticals from $142.00 to $148.00 and gave the company an "outperform" rating in a research report on Tuesday. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an "outperform" rating in a report on Thursday, May 7th. Evercore reiterated an "outperform" rating and issued a $138.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Finally, Stifel Nicolaus set a $136.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $143.40.
Check Out Our Latest Stock Analysis on MIRM
Hedge Funds Weigh In On Mirum Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of MIRM. Cullen Frost Bankers Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth $30,000. Eurizon Capital SGR S.p.A. acquired a new position in Mirum Pharmaceuticals in the fourth quarter worth approximately $32,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at $32,000. Quantbot Technologies LP acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter worth approximately $33,000. Finally, Comerica Bank raised its position in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after purchasing an additional 278 shares during the period.
About Mirum Pharmaceuticals
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
